Pompe Disease (Late-onset) Clinical Trial
Official title:
Prospective, Open-label, Single-arm, Exploratory Study of the Effect and Safety of rhGAA in Patients With Advanced Late-onset Pompe Disease Who Are Receiving Respiratory Support
Pompe disease (also known as glycogen storage disease Type II) is caused by a deficiency of a critical enzyme in the body called acid alpha-glucosidase (GAA). Normally, GAA is used by the body's cells to break down glycogen (a stored form of sugar) within specialized structures called lysosomes. In patients with Pompe disease, an excessive amount of glycogen accumulates and is stored in various tissues, especially heart and skeletal muscle, which prevents their normal function. The overall objective is to evaluate the safety and efficacy of rhGAA in patients with advanced Late-onset Pompe disease.
Status | Completed |
Enrollment | 5 |
Est. completion date | June 2007 |
Est. primary completion date | March 2007 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - male or female aged greater than or equal to 18 years - patient's legally authorized guardian(s) must provide signed, informed consent prior to initiation of study; patient's signature required if patient understands informed consent - patient must have a documented deficit in acid alpha-glucosidase (GAA) activity , corresponding to the diagnosis of Pompe disease confirmed by documented genotyping - patient presents with advanced documented symptoms of the disease defined as follows: patient is in a wheel chair and presents diaphragmatic dysfunction and requires invasive ventilation or non invasive ventilation (12 or more hours daily) Exclusion Criteria: - patient has received enzyme replacement therapy with GAA from any source - patient has taken an experimental drug in the 30 days prior to study enrollment, or is currently included in another study involving clinical evaluations; If this is the case, inclusion of the patient in the present study will be subject to prior agreement by Genzyme - major congenital anomaly - clinically important organic disease (except for symptoms related to Pompe disease) or any other medical condition, serious intercurrent illness, or other extenuating circumstance that, in the physician's opinion should preclude the patient's participation in the study or may reduce survival - pregnancy and breastfeeding (women of childbearing age must use a medically accepted method of contraception throughout the entire duration of the trial. Male patients must use a medically accepted birth control method throughout the entire duration of the study) |
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
France | Hopital Raymond Poincare | Garches |
Lead Sponsor | Collaborator |
---|---|
Genzyme, a Sanofi Company |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Treatment effect on muscle strength and functional status. | six months and one year | No | |
Primary | Treatment effect on pulmonary function and/or ventilation conditions. | six months and one year | No | |
Primary | Treatment effect on cardiomyopathy noted at inclusion | six months and one year | No | |
Primary | Treatment effect on fatigue. | six months and one year | No | |
Primary | Treatment effect on quality of life. | six months and one year | No | |
Primary | Treatment effect on muscular atrophy. | six months and one year | No | |
Primary | Overall patient satisfaction with treatment (visual analog scale). | six months and one year | No | |
Primary | Pharmacodynamics assessment. | six months and one year | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00158600 -
A Placebo-Controlled Study of Safety and Effectiveness of Myozyme (Alglucosidase Alfa) in Patients With Late-Onset Pompe Disease
|
Phase 3 | |
Recruiting |
NCT04174105 -
Gene Transfer Study in Patients With Late Onset Pompe Disease
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04093349 -
A Gene Transfer Study for Late-Onset Pompe Disease (RESOLUTE)
|
Phase 1/Phase 2 | |
Completed |
NCT03285126 -
Pompe Gene Therapy- Screening for Eligibility
|
||
Recruiting |
NCT05083806 -
MSOT in Pompe Disease
|
N/A | |
Recruiting |
NCT05272969 -
Pompe & Pain - Study to Assess Nociceptive Pain in Adult Patients With Pompe Disease
|
||
Active, not recruiting |
NCT03694561 -
Developing a Management Approach for Patients With "Late-Onset" Pompe Disease
|
||
Completed |
NCT00731081 -
Study About the Evolution of Severe Late Onset Pompe Disease Patient With Pulmonary Dysfunction and Receiving Myozyme®
|
N/A | |
Completed |
NCT00455195 -
Late-Onset Treatment Study Extension Protocol
|
Phase 4 | |
Recruiting |
NCT05951790 -
Inspiratory Muscle Training (IMT) in Adult People With Pompe Disease
|
N/A | |
Completed |
NCT01288027 -
Exploratory Muscle Biopsy Assessment Study in Patients With Late-Onset Pompe Disease Treated With Alglucosidase Alfa
|
Phase 4 | |
Recruiting |
NCT00567073 -
Pompe Pregnancy Sub-Registry
|
||
Completed |
NCT03893240 -
Neutralizing Antibody Seroprevalence Study With a Retrospective Component in Participants With Late-Onset Pompe Disease
|
N/A | |
Withdrawn |
NCT04094948 -
Phase II Clinical Trial of Clenbuterol in Adult Patients With Pompe Disease
|
Phase 2 | |
Completed |
NCT00250939 -
A Study of rhGAA in Patients With Late-Onset Pompe Disease
|
Phase 2 | |
Recruiting |
NCT03911505 -
ZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPD
|
Phase 3 | |
Recruiting |
NCT06150820 -
A Study About Antibody Levels and Biomarkers in the Blood in People With Late-onset Pompe Disease
|
N/A | |
Completed |
NCT03729362 -
A Study Comparing ATB200/AT2221 With Alglucosidase Alfa/Placebo in Adult Subjects With Late-onset Pompe Disease
|
Phase 3 | |
Not yet recruiting |
NCT06178432 -
Evaluation of the Safety, Tolerability and Efficacy of Gene Therapy Drug for Late Onset Pompe Disease (LOPD)
|
Early Phase 1 | |
Active, not recruiting |
NCT04138277 -
A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With LOPD
|
Phase 3 |